Republic Services Inc
Change company Symbol lookup
Select an option...
RSG Republic Services Inc
AAPL Apple Inc
CYBN Cybin Inc
LEN.B Lennar Corp
STLD Steel Dynamics Inc
GOEVW Canoo Equity Warrant Exp 21st Dec 2025 *W EXP 12/21/2025
GNBT Generex Biotechnology Corp
MFA MFA Financial Inc
GOOG Alphabet Inc
ADILW Adial Pharmaceuticals Equity Warrants Exp 31 July 2023 *W EXP 07/31/2023
Go

Industrials : Commercial Services & Supplies | Large Cap Blend
Company profile

Republic Services, Inc. is a provider of environmental services in the United States. Through its subsidiaries, transfer stations, recycling centers and landfills, it focuses on providing effective and reliable environmental services and solutions to make proper recycling and waste disposal for its customers. The Company operates through three segments Group 1, Group 2 and Environmental Solutions. Group 1 segment primarily consists of geographic areas located in the western United States. Group 2 segment primarily consists of geographic areas located in the southeastern and mid-western United States, and the eastern seaboard of the United States. Its Environmental Solutions segment provides environmental solutions for daily operations of industrial, petrochemical and refining facilities across the United States and Canada. The Company is engaged in 77 landfill gas-to-energy and other renewable energy projects and had post-closure responsibility for 124 closed landfills.

Premarket

Last Trade
Delayed
$132.40
-1.01 (-0.76%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$133.41
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
50

10-day average volume:
1,211,841
50

Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes

7:00 pm ET August 1, 2022 (BusinessWire) Print

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE rt-CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. This marks the first time a rt-CGM, with no scanning and no finger pricks+, will be available to people with diabetes at the pharmacy level.

Karen Baxter, Vice President, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England, Wales, Scotland and Northern Ireland drug tariff is enormous progress towards improving choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning. We are incredibly proud of the diabetes community and are working hard to make it easier for them to access the best technology possible to manage their diabetes. As a next step, we will be working closely with healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and wider availability of Dexcom CGM."

As of 1 August, patients will receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery once prescribed, after which they can go to the pharmacy for their repeat prescription. This is an incredible step forward following the new guidelines from the National Institute for Care and Excellence (NICE) which recommends adults with type 1 diabetes should be offered a choice of glucose sensor, children should be offered rt-CGM and people with type 2 diabetes using insulin can be considered for rt-CGM as an alternative to their current sensor. Dexcom ONE is part of a range of CGM systems offered by Dexcom for people with diabetes in the UK that also includes the Dexcom G6 and the upcoming Dexcom G7. With the new portfolio of products, Dexcom meets the entire criteria set out by NICE.

National NHS Specialty Adviser for Diabetes, Professor Partha Kar: "The next step in the evolution of type 1 diabetes technology continues to unfold and at NHS England, we are thrilled to be part of the solution. With Dexcom ONE on prescription, more people will have access to potentially life changing CGM technology, leading to better health outcomes and more choice for people with diabetes."

Dexcom ONE is a smart, effective and easy to use wearable sensor and transmitter for those looking for simple diabetes management, bringing you everything you know and love about Dexcom:

By continuously monitoring glucose levels in real-time and sending values wirelessly to a compatible smart device* via the Dexcom ONE mobile app or receiver, the technology eliminates the need for painful finger pricks+ and burdensome scanning while providing a complete picture of glucose levels and trends The user-friendly app and receiver display trend arrows to show the speed and direction that glucose levels are heading, touting exceptional accuracy + to help make in the moment treatment decisions easier A range of customisable alerts warn of potentially dangerous high or low glucose events so action can be taken, with a delayed first alert feature to avoid alarm fatigue Access to Dexcom Clarity data management software provides remote data sharing with HCPs, as well as trends and patterns, 24/7

For more information, visit the Dexcom website at https://www.dexcom.com/en-GB.

Dexcom received CE Mark for Dexcom ONE for people with diabetes ages two years and up in February 2022.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

*Smart device sold separately. For a list of compatible devices, visit www.dexcom.com/en-GB/compatibility

+If your glucose alerts and readings from Dexcom ONE do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

+ Dexcom ONE User Guides

(C) 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6 and Dexcom G7 are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005650/en/

SOURCE: DexCom, Inc.

Allison+Partners for Dexcom
Email: dexcomUK@allisonpr.com
comtex tracking

COMTEX_411370088/1006/2022-08-01T19:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.